Actinic Keratosis

Michael O'Donoghue, MD, shares insights on actinic keratosis management, emphasizing personalized therapy strategies.

Discover expert insights on cutaneous oncology from George Martin, MD, focusing on innovative treatments for skin cancers at Maui Derm NP+PA Fall.

Biofrontera advances closer to expanding the Ameluz PDT label, as phase 3 follow-up data on actinic keratoses are expected next year.

Discover innovative strategies for AK treatment from Darrell Rigel, MD, MS, at the latest Fall Clinical PA/NP conference.

Sun Pharma's innovative BLU-U device gains FDA approval, revolutionizing actinic keratosis treatment with advanced blue light therapy.

The social media campaign aims to educate, inspire prevention, and support actinic keratosis awareness leading up to Global AK Awareness Day on May 24.

Solid organ transplant recipients saw a 79.6% decrease in lesions 12 weeks after the treatment sessions.

The phase 2 trial of bimiralisib gel shows promising efficacy and safety for actinic keratosis, with up to 70% lesion clearance.

The company showcased advancements in tirbanibulin and its early-stage antibody LAD191.

Follow-up phase 3 data showed BF-200 ALA to be a safe and effective therapy for AK, when compared to placebo.

Experts highlight the versatility and patient-centered approach of PDT with red light, emphasizing its effectiveness for AK, skin rejuvenation, and superficial cancers.

Australian researchers found 5-FU to be the cheapest AK treatment, compared to imiquimod and MAL-photodynamic therapy.

The novel drug demonstrated tolerability for AK treatment when applied to a field of 100 cm2 of the face or scalp.

The expanded dosage aims to provide healthcare providers with greater flexibility in treating larger or multiple areas affected by AK.

A recent study indicated that 43.3% of lesions achieved a high efficacy score following Alexandrite laser therapy.